Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 88Lung Neoplasms 53Carcinoma, Hepatocellular 43Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 23Cholangiocarcinoma 22Urinary Bladder Neoplasms 21Colorectal Neoplasms 21Pancreatic Neoplasms 20Ovarian Neoplasms 17Triple Negative Breast Neoplasms 16Biliary Tract Neoplasms 16Neoplasm Metastasis 13Head and Neck Neoplasms 12Neoplasms 11Carcinoma, Renal Cell 11Liver Neoplasms 9Endometrial Neoplasms 9Carcinoma, Transitional Cell 9Uterine Cervical Neoplasms 7Esophageal Neoplasms 7Carcinoma, Squamous Cell 7Adenocarcinoma Of Esophagus 7Recurrence 6Prostatic Neoplasms 6Mesothelioma, Malignant 6Melanoma 6Gallbladder Neoplasms 6Fallopian Tube Neoplasms 6

Interventions

pembrolizumab 12Radiotherapy 9avelumab 8Nivolumab 8cemiplimab 4Radiation 4Ipilimumab 4poly ICLC 3atezolizumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Etoposide 3Cyclophosphamide 3talimogene laherparepvec 2lutetium Lu 177 dotatate 2fludarabine phosphate 2fludarabine 2durvalumab 2aldesleukin 2Interferon-beta 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Cisplatin 2Carboplatin 2Biopsy 2veliparib 1vatalanib 1tremelimumab 1tocilizumab 1temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Merkel Cell × durvalumab × Clear all
NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Ludwig Institute for Cancer Research

Phase 1/2 Completed
58 enrolled 24 charts
BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡